Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529–41.

Article  PubMed  CAS  Google Scholar 

Carey LA, Loirat D, Punie K, Bardia A, Diéras V, Dalenc F, et al. Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis. NPJ Breast Cancer. 2022;8:72.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bardia A, Rugo HS, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Kalinsky K, Cortés J, Shaughnessy JO, Diéras V, Carey LA, Gianni L, Piccart-Gebhart M, Loibl S, Yoon OK, Pan Y, Hofsess S, Phan S-C, Hurvitz SA. Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression. J Clin Oncol. 2024;42(15):1738–44.

Article  PubMed  CAS  Google Scholar 

Modi S, Saura C, Yamashita T, Park YH, Kim S-B, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382:610–21.

Article  PubMed  CAS  Google Scholar 

Cortés J, Kim S-B, Chung W-P, Im S-A, Park YH, Hegg R, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386:1143–54.

Article  PubMed  Google Scholar 

Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9–20.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wahby S, Fashoyin-Aje L, Osgood CL, Cheng J, Fiero MH, Zhang L, et al. FDA approval summary: accelerated approval of sacituzumab govitecan-hziy for third-line treatment of metastatic triple-negative breast cancer. Clin Cancer Res. 2021;27:1850–4.

Article  PubMed  CAS  Google Scholar 

Michaleas S, Moreno Oliver A, Mueller-Berghaus J, Sarac SB, van der Elst ME, Müller-Egert S, et al. The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer. ESMO Open. 2022;7:100497.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Narayan P, Osgood CL, Singh H, Chiu H-J, Ricks TK, Chiu Yuen Chow E, et al. FDA approval summary: fam-trastuzumab deruxtecan-nxki for the treatment of unresectable or metastatic HER2-positive breast cancer. Clin Cancer Res. 2021;27:4478–85.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Narayan P, Dilawari A, Osgood C, Feng Z, Bloomquist E, Pierce WF, et al. US food and drug administration approval summary: fam-trastuzumab deruxtecan-nxki for human epidermal growth factor receptor 2-low unresectable or metastatic breast cancer. J Clin Oncol. 2023;41:2108–16.

Article  PubMed  CAS  Google Scholar 

Galvin A, Courtinard C, Bouteiller F, Gourgou S, Dalenc F, Jacot W, et al. First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort. Eur J Cancer. 2024;196:113422.

Article  PubMed  Google Scholar 

Magnoni F, Corso G, Maisonneuve P, Bianchi B, Accardo G, Sangalli C, et al. Comparison of long-term outcome between clinically high risk lobular versus ductal breast cancer: a propensity score matched study. EClinicalMedicine. 2024;71:102552.

Article  PubMed  PubMed Central  Google Scholar 

Ligorio F, Zambelli L, Fucà G, Lobefaro R, Santamaria M, Zattarin E, et al. Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications. Ther Adv Med Oncol. 2022;14:17588359221079124.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Largillier R, Ferrero J-M, Doyen J, Barriere J, Namer M, Mari V, et al. Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol. 2008;19:2012–9.

Article  PubMed  PubMed Central  CAS  Google Scholar 

De Moura A, Loirat D, Vaillant S, Korbi S, Kiavue N, Bello Roufai D, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases. Breast Cancer. 2024;31:572–80.

de la Cruz-Ku G, Chambergo-Michilot D, Torres-Roman JS, Rebaza P, Pinto J, Araujo J, et al. Neutrophil-to-lymphocyte ratio predicts early mortality in females with metastatic triple-negative breast cancer. PLoS One. 2020;15:e0243447.

Article  PubMed  PubMed Central  Google Scholar 

O’Shaughnessy J, DeMichele A, Ma CX, Richards P, Yardley DA, Wright GS, et al. A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation. Breast Cancer Res Treat. 2018;170:547–57.

Article  PubMed  Google Scholar 

Annovazzi A, Rea S, Maccora D, Pizzuti L, Ferretti G, Vici P, et al. Prognostic value of [18F]-FDG PET/CT in patients with meta-static breast cancer treated with cyclin-dependent inhibitors. Front Oncol. 2023;13:1193174.

Article  PubMed  PubMed Central  Google Scholar 

Marinelli B, Espinet-Col C, Ulaner GA, McArthur HL, Gonen M, Jochelson M, et al. Prognostic value of FDG PET/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients. Am J Nucl Med Mol Imaging. 2016;6:120–7.

PubMed  PubMed Central  Google Scholar 

Vaz SC, Woll JPP, Cardoso F, Groheux D, Cook GJR, Ulaner GA, et al. Joint EANM-SNMMI guideline on the roleof 2-[18F]FDG PET/CT in no special type breast cancer: (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA). Eur J Nucl Med Mol Imaging. 2024;51:2706–32.

Article  PubMed  PubMed Central  Google Scholar 

Seban R-D, Arnaud E, Loirat D, Cabel L, Cottu P, Djerroudi L, et al. [18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab. Eur J Nucl Med Mol Imaging. 2023;50:4024–35.

Article  PubMed  CAS  Google Scholar 

Pak K, Seok JW, Kim HY, Nguyen TL, Kim K, Kim SJ, et al. Prognostic value of metabolic tumor volume and total lesion glycolysis in breast cancer: a meta-analysis. Nucl Med Commun. 2020;41:824–9.

Article  PubMed  Google Scholar 

Seban R-D, Rouzier R, Latouche A, Deleval N, Guinebretiere J-M, Buvat I, et al. Total metabolic tumor volume and spleen metabolism on baseline [18F]-FDG PET/CT as independent prognostic biomarkers of recurrence in resected breast cancer. Eur J Nucl Med Mol Imaging. 2021;48:3560–70.

Cottereau A-S, Nioche C, Dirand A-S, Clerc J, Morschhauser F, Casasnovas O, et al. 18F-FDG PET dissemination features in diffuse large B-cell lymphoma are predictive of outcome. J Nucl Med. 2020;61:40–5.

Article  PubMed  PubMed Central  Google Scholar 

Cottereau A-S, Meignan M, Nioche C, Capobianco N, Clerc J, Chartier L, et al. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT†. Ann Oncol. 2021;32:404–11.

Article  PubMed  Google Scholar 

Girum KB, Rebaud L, Cottereau A-S, Meignan M, Clerc J, Vercellino L, et al. 18F-FDG PET maximum-intensity projections and artificial intelligence: a win-win combination to easily measure prognostic biomarkers in DLBCL patients. J Nucl Med. 2022;63:1925–32.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Eertink JJ, van de Brug T, Wiegers SE, Zwezerijnen GJC, Pfaehler EAG, Lugtenburg PJ, et al. 18F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2022;49:932–42.

Article  PubMed  Google Scholar 

Nioche C, Orlhac F, Boughdad S, Reuzé S, Goya-Outi J, Robert C, et al. LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res. 2018;78:4786–9.

Article  PubMed  CAS  Google Scholar 

Najid S, Seban R-D, Champion L, De Moura A, Sebbag C, Salaün H, et al. Clinical utility of pre-therapeutic [18F]FDG PET/CT imaging for predicting outcomes in breast cancer. J Clin Med. 2023;12:5487.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tan W, Zhang Y, Wang J, Zheng Z, Xing L, Sun X. FDG PET/CT tumor dissemination characteristic predicts the outcome of first-line systemic therapy in non-small cell lung cancer. Acad Radiol. 2023;30:2904–12.

Article  PubMed  Google Scholar 

Chen W, Hoffmann AD, Liu H, Liu X. Organotropism: new insights into molecular mechanisms of breast cancer metastasis. npj Precis Onc. 2018;2:1–12.